MedTrace Logo

Allopregnanolone Regenerative Therapeutic for Early Alzheimer's Disease: Intramuscular Study

NCT03748303 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2026-03-13

No results posted yet for this study

Summary

The purpose of this study is to identifying the intramuscular dose equivalent to the 4mg intravenous dose and assess its safety and tolerability as a weekly injection.

Conditions

  • Alzheimer Dementia

Interventions

DRUG

Allopregnanolone

Administration of weekly IM injections of Allopregnanolone.

Sponsors & Collaborators

  • University of Southern California

    collaborator OTHER

  • Alzheimer's Association

    collaborator OTHER

  • University of Arizona

    lead OTHER

Principal Investigators

  • Roberta D Brinton, PhD · University of Arizona

  • Lon S Schneider, MD, MS · University of Southern California

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-01
Primary Completion
2022-12-21
Completion
2022-12-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03748303 on ClinicalTrials.gov